We examined an EGFR exon 19-deleted LU5221 PDX model and observed that upfront combinations with osimertinib and AURKB inhibitor AZD2811 (25 mg/kg) or sequential combination delayed tumor regrowth relative to monotherapy (Fig. 4a, Supplementary Fig. 11A). Here, EGFR is linked to neoplasm.